CYP3A4-mediated Effects of Cranberry and Pomegranate Juices on Alprazolam Pharmacodynamics.

INTRODUCTION: Alprazolam, a frequently prescribed anxiolytic, is extensively metabolized in the liver mostly by the cytochrome P450 3A4 (CYP3A4) enzyme. Cranberry and pomegranate juices, often suggested for their possible therapeutic effects in kidney stone management, have been identified as strong inhibitors of CYP3A4. This raises considerable concerns about possible drug-food interactions that could modify the pharmacodynamic profile of alprazolam. This study aimed to comprehensively assess the pharmacodynamic interactions between alprazolam and these juices, focusing on their collective impact on behavioral and histological results.

METHODS: Molecular docking studies were conducted utilizing AutoDock Vina to assess the binding affinities of active compounds from cranberry and pomegranate juices to the CYP3A4 enzyme, resulting in binding energies of -9.2 and -9.3 kcal/mol, respectively. In vivo tests were performed on adult male Wistar albino rats, which were divided into five experimental groups: control, alprazolam alone, and alprazolam co-administered with cranberry juice, pomegranate juice, or a combination of both. Pharmacodynamic interactions were evaluated via behavioral analyses using the Elevated Plus Maze, Rotarod, and Y-Maze tests to assess anxiety, motor coordination, and cognitive performance. Furthermore, histological analyses of brain tissues were performed to detect neuronal changes and evaluate the degree of neurodegeneration linked to the treatment.

RESULTS: Molecular docking analyses revealed strong binding affinities of anthocyanins from cranberries and ellagic acid from pomegranates to the CYP3A4 enzyme, suggesting their ability to inhibit its activity. Behavioral tests indicated considerable deficits in memory and motor coordination in groups receiving cranberry or pomegranate drinks in conjunction with alprazolam, relative to the alprazolam-only and control groups. Histopathological examination of brain tissues supported these findings, revealing a significant elevation in neuronal degeneration in the coadministration groups compared to controls, indicating a synergistic effect on neurotoxicity.

DISCUSSION: The pharmacodynamic changes observed suggest that the coadministration of cranberry and pomegranate juices with alprazolam alters the drug's effects, likely due to CYP3A4 inhibition by the juices' phytochemicals. These interactions may enhance alprazolam's neuropharmacological effects, resulting in an increased risk of cognitive and motor impairments. These findings underscore the clinical importance of monitoring food-drug interactions, especially in patients using natural products concurrently with CNS-active medications.

CONCLUSION: This study highlights significant pharmacodynamic interactions between alprazolam and cranberry/pomegranate juices, highlighting their potential to influence the drug's therapeutic effectiveness and safety profile. The findings highlight the essential necessity for monitoring when concurrently administering these natural medicines with alprazolam, as their simultaneous usage may result in altered pharmacological effects and increased risk of adverse effects.